Drug interactions
Obinutuzumab + Palifermin
Severity: Moderate
Obinutuzumab and Palifermin: moderate interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Palifermin is a keratinocyte growth factor used to reduce mucositis after myelotoxic chemotherapy. Giving it close to cytotoxic therapy worsened mucositis in studies of chemotherapy. Obinutuzumab is not a classic mucotoxic chemotherapy, so the relevance is uncertain and the concern is extrapolated.
What this interaction means in plain words
Obinutuzumab and Palifermin can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.
Obinutuzumab belongs to Oncology; Palifermin belongs to Miscellaneous.
Why it happens
Palifermin stimulates epithelial cell proliferation, which may increase sensitivity to cytotoxic therapy; this is not established for obinutuzumab.
What to do
If used with cytotoxic chemotherapy, avoid palifermin within 24 hours before, during or after the chemotherapy. Monitor for mucositis.
What to ask your pharmacist
- Should I take them at different times of day?
- Does the dose of either medicine need to change?
- Is there anything I should avoid, such as alcohol or certain foods, while on both?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Obinutuzumab and Palifermin, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 14 days on the web. No card needed.
Other interactions of Obinutuzumab
Other interactions of Palifermin
Frequently asked questions
Can I take Obinutuzumab with Palifermin?
MediHelp rates the interaction as moderate. Obinutuzumab and Palifermin can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Palifermin is a keratinocyte growth factor used to reduce mucositis after myelotoxic chemotherapy. Giving it close to cytotoxic therapy worsened mucositis in studies of chemotherapy. Obinutuzumab is not a classic mucotoxic chemotherapy, so the relevance is uncertain and the concern is extrapolated.
How serious is the interaction between Obinutuzumab and Palifermin?
MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: If used with cytotoxic chemotherapy, avoid palifermin within 24 hours before, during or after the chemotherapy. Monitor for mucositis.
What other medicines interact with Obinutuzumab?
MediHelp also lists interactions of Obinutuzumab with, for example, Measles mumps and rubella vaccine, Adenovirus types 4 and 7 live, Axicabtagene ciloleucel. The full list is on the Obinutuzumab page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
